I-BET151 (GSK1210151A): Selective BET Bromodomain Inhibitor for Cancer Research

Executive Summary: I-BET151 (GSK1210151A) selectively inhibits BET family proteins BRD2, BRD3, and BRD4, with IC50 values of 0.5 μM, 0.25 μM, and 0.79 μM, respectively (APExBIO). This compound disrupts transcriptional programs crucial for cancer progression by blocking BET protein interaction with acetylated histones (Kang et al., 2025). I-BET151 induces cell cycle arrest and apoptosis in myeloma and glioblastoma models, both in vitro and in vivo. Its performance is verified through dose-dependent apoptosis and G1 phase arrest assays, confirming robust epigenetic modulation. The product is widely used in research targeting BET-driven malignancies, notably MLL-fusion leukemia and super-enhancer-associated cancers.

Biological Rationale

BET proteins, including BRD2, BRD3, and BRD4, recognize acetylated lysine residues on histone tails. This interaction regulates gene expression by modulating chromatin structure and transcriptional machinery assembly (Kang et al., 2025). Dysregulated BET signaling is implicated in oncogenesis, particularly in cancers reliant on super-enhancer-driven transcriptional programs, such as prostate cancer and MLL-fusion leukemia. Disruption of BET function impairs oncogenic drivers, including MYC and SLC7A11, thereby inhibiting tumor proliferation and survival. I-BET151 targets this pathway, offering a rational approach to modulate epigenetic regulation in cancer biology. For a broader discussion of BET signaling in oncology, see this article, which I-BET151-focused content extends by providing detailed mechanistic benchmarks and specific assay results.

Mechanism of Action of I-BET151 (GSK1210151A)

I-BET151 functions as a competitive inhibitor at the bromodomain pocket of BRD2, BRD3, and BRD4. By binding to these domains, it prevents BET proteins from associating with acetylated histones, disrupting recruitment of transcriptional co-activators and RNA polymerase II to target promoters (APExBIO). This results in global downregulation of super-enhancer-driven genes, including oncogenes such as MYC and anti-apoptotic regulators (Annexin-V-APC resource; this article clarifies the direct in vitro and in vivo evidence base for apoptosis induction by I-BET151 as opposed to higher-level overviews). In cell-based assays, I-BET151 induces G1 phase cell cycle arrest and promotes apoptosis in a dose- and time-dependent manner, especially in glioblastoma U87MG and myeloma cell lines.

Evidence & Benchmarks

• I-BET151 inhibits BRD2, BRD3, and BRD4 with IC50 values of 0.5 μM, 0.25 μM, and 0.79 μM, respectively (APExBIO).
• In glioblastoma U87MG cells, I-BET151 triggers G1 phase cell cycle arrest and increases apoptotic markers in a time- and dose-dependent manner (Kang et al., 2025).
• Mouse xenograft models of myeloma and glioblastoma treated with I-BET151 show significant reduction in tumor volume compared to controls (Kang et al., 2025).
• I-BET151 improves survival in leukemia models driven by BET protein overexpression (Kang et al., 2025).
• I-BET151 is highly soluble in DMSO (≥41.5 mg/mL) and ethanol (≥19.5 mg/mL), but insoluble in water, facilitating diverse in vitro applications (APExBIO).
• Optimal storage at -20°C preserves compound integrity for research workflows (APExBIO).

Applications, Limits & Misconceptions

I-BET151 is primarily deployed in research targeting epigenetic regulation, transcriptional modulation, and BET-driven malignancies. It enables detailed apoptosis and cell cycle arrest assays, especially in MLL-fusion leukemia, glioblastoma, and prostate cancer models driven by super-enhancers. For robust, reproducible integration in cancer biology workflows, I-BET151 (GSK1210151A) B1500 kits are available from APExBIO. For a discussion on troubleshooting and advanced protocol integration, this PrecisionFDA article provides protocol enhancements, which this article updates with the latest in vivo benchmarks and stability parameters.

Common Pitfalls or Misconceptions

• I-BET151 is not effective in models lacking BET protein expression. Activity requires presence of BRD2/3/4 in the target cell.
• The compound is insoluble in aqueous buffers. Use only DMSO or ethanol for stock solutions; do not attempt direct suspension in water.
• Chronic storage of solutions at room temperature leads to degradation. Store at -20°C and use freshly prepared solutions for each experiment.
• I-BET151 does not directly induce disulfidptosis. It modulates transcriptional programs that may regulate cell death mechanisms, but does not trigger this pathway independently of cellular context (Kang et al., 2025).
• BET inhibition may not sensitize all tumor types to standard chemotherapies. Some resistant cancer models require combination strategies for efficacy.

Workflow Integration & Parameters

For optimal solubility, dissolve I-BET151 in DMSO up to ≥41.5 mg/mL or ethanol up to ≥19.5 mg/mL. Warm to 37°C or apply an ultrasonic bath for fully dissolved stock solutions (APExBIO). Store dry powder and solutions at -20°C; use solutions within 2–4 weeks. In apoptosis and cell cycle arrest assays, typical working concentrations range from 0.1 μM to 10 μM, depending on cell type and exposure time. For in vivo mouse xenograft studies, I-BET151 is administered by intraperitoneal injection at doses of 10–30 mg/kg/day, with tumor volume monitored regularly (Kang et al., 2025). For further details on robust workflow design, see this guide, which this article extends with quantitative benchmarks for solubility and storage.

Conclusion & Outlook

I-BET151 (GSK1210151A) is a validated, selective BET bromodomain inhibitor for advanced cancer research and epigenetic modulation. Its robust inhibitory profile against BRD2, BRD3, and BRD4, coupled with clear performance in apoptosis and cell cycle assays, makes it a pivotal tool in dissecting BET protein signaling pathways. As the understanding of super-enhancer-driven oncogenesis deepens, I-BET151 remains central in research on transcriptional modulation and next-generation therapeutic strategies. For product specifications and ordering, visit the official APExBIO I-BET151 (GSK1210151A) page.